Loading
EO
Elevation Oncology, Inc. Stock: price and insider trades · United States
Elevation Oncology, Inc.: what insiders have been doing
Only a handful of insider records exist for Elevation Oncology, Inc., the last one from 24 July 2025, too few to describe a trend. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
31
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€3M
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-39.7M
Last declaration on 24 July 2025
Declarations31 total
47,330 shares@ US$0.36100.0% of flowCommon StockSEC:0001415889-25-020238:0
37,957 shares@ US$0.36100.0% of flowCommon StockSEC:0001415889-25-020235:0
12,560 sharesCommon StockSEC:0001415889-25-017667:0
2,643 sharesCommon StockSEC:0001415889-25-013621:0
6,250 sharesCommon StockSEC:0001415889-25-013611:0
12,562 sharesCommon StockSEC:0001415889-25-008380:0
25,000 sharesCommon StockSEC:0001415889-25-004589:0
9,375 sharesCommon StockSEC:0001415889-25-004595:0
17,500 sharesCommon StockSEC:0001415889-25-004620:0
9,375 sharesCommon StockSEC:0001415889-25-004609:0
12,563 sharesCommon StockSEC:0001415889-24-029728:0
300 sharesCommon StockSEC:0001415889-24-027199:0
12,562 sharesCommon StockSEC:0001415889-24-023607:0
300 sharesCommon StockSEC:0001415889-24-021570:0
12,562 sharesCommon StockSEC:0001415889-24-017385:0
300 sharesCommon StockSEC:0001415889-24-013471:0
12,562 sharesCommon StockSEC:0001415889-24-008492:0
1,200 sharesCommon StockSEC:0001415889-24-004400:0
12,563 sharesCommon StockSEC:0001415889-23-016727:0
12,562 sharesCommon StockSEC:0001415889-23-013411:0
15,777 shares0Common StockSEC:0001415889-23-012907:0
12,563 sharesCommon StockSEC:0001415889-23-010088:0
12,563 sharesCommon StockSEC:0001415889-23-005216:0
50,249 sharesCommon StockSEC:0001415889-22-012784:0
31,553 shares0Common StockSEC:0001209191-22-038758:0
25 of 31 declarations
About Elevation Oncology, Inc.
Elevation Oncology, Inc. is a United States-based biopharmaceutical company that was listed on the Nasdaq market under the ticker ELEV. The company was founded in 2019 under the former name 14ner Oncology, Inc. and later renamed Elevation Oncology, Inc. Its business has been built around the discovery and development of selective cancer therapies for patients with solid tumors that have significant unmet medical needs. According to its SEC filings, the company’s principal executive offices are in Boston, Massachusetts, and it does not maintain a traditional operating corporate headquarters footprint, which is consistent with a capital-efficient biotech structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000155837025002397/elev-20241231x10k.htm?utm_source=openai))
From a strategic standpoint, Elevation Oncology positioned itself as an oncology precision-medicine company with a focus on antibody-drug conjugates, or ADCs. Its pipeline historically included EO-3021, a Claudin 18.2 ADC, and EO-1022, a HER3-targeted ADC. The company’s public disclosures in 2025 show a sharp narrowing of the pipeline: in March 2025, it announced it was discontinuing EO-3021 and evaluating strategic alternatives to maximize shareholder value, and in June 2025 it terminated the related CSPC license agreement. At the same time, the company highlighted EO-1022 as its lead remaining program, describing it as a potentially differentiated HER3 ADC for HER3-expressing solid tumors, with an IND filing expected in 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000155837025007801/elev-20250331x10q.htm?utm_source=openai))
Read moreShow less
For investors, the company’s competitive position was that of an early-stage biotech operating in a highly contested oncology landscape. Its appeal came from targeted cancer biology, biomarker-driven patient selection, and the broader market interest in ADC platforms. However, as with most development-stage oncology names, the investment case depended heavily on preclinical and clinical de-risking, regulatory progress, and access to capital rather than current commercial revenues. In other words, the stock was driven primarily by pipeline execution and event risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000155837025002397/elev-20241231x10k.htm?utm_source=openai))
The most important recent corporate event was the merger agreement announced on June 8, 2025, under which Concentra Biosciences agreed to acquire Elevation Oncology for $0.36 in cash per share plus a contingent value right. Subsequent SEC filings and Form 4 insider-transaction documents in July 2025 reflect the merger process and related equity disposition mechanics. This is a decisive development for any investor analysis, because it effectively shifted the company from a standalone Nasdaq-listed oncology developer into a transaction-driven situation with a defined exit framework. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/tm2517439d1_8k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
